Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies

Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat relapsed or refractory hematological malignancies. However, the adverse effects of CAR-T cell therapies are complex and can be challenging to diagnose and treat. In this review, we summarize the major adverse events,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Chieh, Nguyen, John, Yen, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590030/
https://www.ncbi.nlm.nih.gov/pubmed/37864230
http://dx.doi.org/10.1186/s12929-023-00982-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590030/
https://www.ncbi.nlm.nih.gov/pubmed/37864230
http://dx.doi.org/10.1186/s12929-023-00982-8

Ejemplares similares